This transaction was executed on December 30, 2024, leaving Kakkis with 2,183,985 shares owned indirectly through the Emil Kakkis and Jenny Soriano Living Trust. The filing also notes that Kakkis holds 564,605 shares directly, which include shares underlying restricted stock units (RSUs) subject to vesting conditions. This sale is part of a prearranged 10b5-1 trading plan, allowing executives to plan stock transactions in advance, thereby avoiding accusations of insider trading. InvestingPro analysis reveals strong liquidity with a current ratio of 2.81, while analysts maintain a bullish consensus on the stock. Get access to the complete Ultragenyx Pro Research Report and 6 additional ProTips through InvestingPro. InvestingPro analysis reveals strong liquidity with a current ratio of 2.81, while analysts maintain a bullish consensus on the stock. Get access to the complete Ultragenyx Pro Research Report and 6 additional ProTips through InvestingPro. This transaction was executed on December 30, 2024, leaving Kakkis with 2,183,985 shares owned indirectly through the Emil Kakkis and Jenny Soriano Living Trust.
The filing also notes that Kakkis holds 564,605 shares directly, which include shares underlying restricted stock units (RSUs) subject to vesting conditions. This sale is part of a prearranged 10b5-1 trading plan, allowing executives to plan stock transactions in advance, thereby avoiding accusations of insider trading.
In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc. has made significant progress in its clinical pipeline. The company reported a 42% year-over-year increase in Q3 2024 revenue, totaling $139 million. However, a net loss of $134 million was also recorded for the same quarter. H.C. Wainwright has maintained its Buy rating for Ultragenyx, reflecting confidence in the company’s ongoing clinical developments.
Ultragenyx has initiated the pivotal Phase 3 Aspire study for GTX-102, an experimental treatment for Angelman syndrome. The company has also sought FDA approval for its Sanfilippo A gene therapy, UX111. Both developments mark substantial strides in the treatment of rare neurodegenerative diseases.
Analysts from H.C. Wainwright and others maintain a strong buy consensus on the stock, with price targets ranging from $48 to $140 per share. The company, led by CEO Emil Kakkis, anticipates reaching GAAP profitability by the end of 2026 and is preparing for Biologics License Application submissions for treatments targeting rare diseases. These are recent developments in the company’s ongoing efforts to advance its clinical pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.